DA-3501 (AT-211): Evaluation of immune-mediated antitumor activity and combination immunotherapy potential of a site-specific CLDN18.2-targeting antibody-drug conjugate (ADC) (AACR 2026) - Mar 18, 2026 - Abstract #5644/14; Pres time: Apr 21, 2026; 02:00 PM - 05:00 PM; Location: Section 10; "However, acquired resistance to CLDN18.2-directed antibodies such as zolbetuximab and trastuzumab highlights the need for next-generation therapeutics with distinct mechanisms of action. DA-3501 (AT-211) is a site-selectively conjugated CLDN18.2-targeting ADC that exerts strong immune-mediated antitumor effects, even in models derived from patients resistant to existing antibody therapies. These results highlight the dual mechanism of action of DA-3501—combining direct cytotoxicity and Fc-driven immune activation—and support the development of rational ADC-immunotherapy combinations as a promising strategy in the evolving landscape of ADC-based cancer treatment."
ADC • IO biomarker • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18
|
|
Kyoung-Ho Pyo1; Seong-Hyun Park1; Dongsop Lee2; Haneol Kim2; Younggyu Kong2; Younggeun Lee1; Hojin Yeom1; Sowon Aum1; Sun Hee Park1; Huijo Oh1; Cheyeon Kim1; Hyeonseok Jin2; Hyeonseok Jin2; Aera Lee2; Hojeong Hong2; Ju Hwan Kim1; Hyungseok Choi2; Mi-Kyung Kim2; Taedong Han1
|